Is Novo Nordisk a Buy After Its New Obesity Candidate ' s Success in a Clinical Trial?

Shares of Novo Nordisk (NYSE: NVO) rose to a new all-time high on Thursday, March 7. The market was responding to encouraging results from a clinical trial with an experimental weight-management drug called amycretin. Amycretin is an orally available treatment candidate, which could give it a big…#novonordisk #nvo #amycretin #wegovyand #elililly #lly #glp1 #wegovyandozempic #amylin #cagrisema
Source: Reuters: Health - Category: Consumer Health News Source Type: news